GlassScriptPhysician profile
Sherna Madan
NPI 1134242753
$3,853.26
in general payments reported to CMS, 2019-2025
22 companies · $51.44 in 2025
The $51.44 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,078 · 2020: $340 · 2021: $416 · 2022: $231 · 2023: $218 · 2024: $520 · 2025: $51.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $788.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $564.11 | 2019-2020 | |
| Abbvie INC. | $482.34 | 2021-2022 | |
| Mannkind Corporation | $409.83 | 2019-2023 | Afrezza |
| Novo Nordisk INC | $361.41 | 2019-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $356.87 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $315.61 | 2019-2024 | Tepezza, Repatha |
| Alexion Pharmaceuticals, INC. | $312.98 | 2019-2024 | Strensiq |
| Astrazeneca Pharmaceuticals LP | $245.20 | 2019 | |
| Corcept Therapeutics | $235.77 | 2019-2020 | |
| Radius Health, INC. | $192.23 | 2019 | |
| Sanofi-Aventis U.S. LLC | $89.52 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.61 | 2019 | |
| Novartis Pharmaceuticals Corporation | $40.29 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $37.44 | 2019 | |
| Kyowa Kirin, INC. | $29.71 | 2024 | Crysvita |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alfasigma USA, INC. | $28.12 | 2021 | |
| Cmp Pharma, INC. | $21.83 | 2021 | |
| Ascensia Diabetes Care US INC. | $21.37 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.38 | 2022 | |
| Horizon Therapeutics Plc | $20.32 | 2019 | |
| Vertical Pharmaceuticals, LLC | $14.32 | 2019 | |
| Insulet Corporation | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherna Madan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.